Frontiers in nutrition · 2026
The impact of low carbohydrate diet on the plasma proteomic profile of individuals with obesity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alfadda Nora A, Aljuraiban Ghadeer S, Joy Salini Scaria, Elkhateb Heba, Nawaz Shahed, Othman Othman Mahmoud, Alzeer Osama Z, Al Wabel Abdullah Abdulaziz, Alfadda Assim A, Benabdelkamel Hicham
Аннотация
INTRODUCTION: Obesity is a major public health concern worldwide and contributes to multiple metabolic disorders. Low carbohydrate diets (LCDs) have been proposed as an effective strategy for weight management and metabolic improvement; however, the mechanisms underlying LCD-induced molecular changes in individuals with obesity remain incompletely understood. This study aimed to assess the impact of a three-month LCD on the proteomic profile of adults with obesity.
METHODS: Thirty adults (18-50 years) with obesity (BMI ≥ 30 kg/m2) followed an LCD (60-110 g/day) for 3 months. Anthropometric and laboratory measurements were obtained, and blood samples were collected at baseline and endpoint. Changes in the plasma proteomic profile were evaluated using an untargeted label-free quantitative proteomics approach (LC-MS/MS), complemented by bioinformatics and pathway network analyses. Anthropometric and biochemical data were analyzed using paired-sample t-tests and Wilcoxon signed-rank tests in IBM SPSS®.
RESULTS: Overall, the LCD was associated with significant reductions in body weight, BMI, waist and hip circumferences, fat mass and percentage, GGT, triglycerides, and HbA1c (paired t-test, p < 0.001). Participants were stratified by total weight loss percentage into responders (≥5%; n = 15) and non-responders (<5%; n = 15). Label-free proteomics identified 90 significantly dysregulated proteins in responders (53 upregulated, 37 downregulated) and 183 in non-responders (111 upregulated, 72 downregulated) between baseline and endpoint. Significantly dysregulated proteins in the responder group included beta-enolase (ENO3) and CREG1 (both upregulated), and tenascin (downregulated). In the non-responder group, insulin-like growth factor-binding protein 7, acyl-CoA-binding protein, and talin-1 were significantly downregulated. Pathway network analysis in responders was centered around dysregulation of TNF, IL6, IFNG, APP, DEGS1, and ENO3 and was related to cell-mediated immune response, cell-to-cell signaling and interaction, and cellular movement. In non-responders, the top network was centered around PGAM1, PDIA3, PHGDH, and EGFR and was associated with cardiovascular disease, dermatological diseases and conditions, and organismal injury and abnormalities.
CONCLUSION: A three-month LCD significantly improved anthropometric and metabolic parameters in adults with obesity and was associated with marked changes in the plasma proteome. Distinct proteomic signatures between responders and non-responders highlight inter-individual variability in biological response, supporting the potential of plasma proteomics for biomarker discovery and precision nutrition in obesity management.
METHODS: Thirty adults (18-50 years) with obesity (BMI ≥ 30 kg/m2) followed an LCD (60-110 g/day) for 3 months. Anthropometric and laboratory measurements were obtained, and blood samples were collected at baseline and endpoint. Changes in the plasma proteomic profile were evaluated using an untargeted label-free quantitative proteomics approach (LC-MS/MS), complemented by bioinformatics and pathway network analyses. Anthropometric and biochemical data were analyzed using paired-sample t-tests and Wilcoxon signed-rank tests in IBM SPSS®.
RESULTS: Overall, the LCD was associated with significant reductions in body weight, BMI, waist and hip circumferences, fat mass and percentage, GGT, triglycerides, and HbA1c (paired t-test, p < 0.001). Participants were stratified by total weight loss percentage into responders (≥5%; n = 15) and non-responders (<5%; n = 15). Label-free proteomics identified 90 significantly dysregulated proteins in responders (53 upregulated, 37 downregulated) and 183 in non-responders (111 upregulated, 72 downregulated) between baseline and endpoint. Significantly dysregulated proteins in the responder group included beta-enolase (ENO3) and CREG1 (both upregulated), and tenascin (downregulated). In the non-responder group, insulin-like growth factor-binding protein 7, acyl-CoA-binding protein, and talin-1 were significantly downregulated. Pathway network analysis in responders was centered around dysregulation of TNF, IL6, IFNG, APP, DEGS1, and ENO3 and was related to cell-mediated immune response, cell-to-cell signaling and interaction, and cellular movement. In non-responders, the top network was centered around PGAM1, PDIA3, PHGDH, and EGFR and was associated with cardiovascular disease, dermatological diseases and conditions, and organismal injury and abnormalities.
CONCLUSION: A three-month LCD significantly improved anthropometric and metabolic parameters in adults with obesity and was associated with marked changes in the plasma proteome. Distinct proteomic signatures between responders and non-responders highlight inter-individual variability in biological response, supporting the potential of plasma proteomics for biomarker discovery and precision nutrition in obesity management.